Device for tendon and ligament treatment
View Patent ↗Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include acellular arterial tissue matrices that facilitate regrowth of the damaged tissue.
1. A method for treating a tendon or ligament, comprising:
selecting a tendon or ligament of a hand, wrist, or finger in need of treatment;
selecting an arterial tissue matrix from which substantially all the native cells have been removed; and
contacting the arterial tissue matrix with at least a portion of the tendon or ligament in need of treatment by wrapping the arterial tissue matrix around the tendon or ligament with a basement membrane of the arterial tissue matrix facing away from the tendon or ligament.
2. The method of claim 1 , wherein the arterial tissue matrix comprises a porcine arterial tissue matrix.
3. The method of claim 1 , wherein the tendon or ligament in need of treatment comprises an injury selected from a strain, a tear, or a gap.
4. The method of claim 1 , further comprising adding a bioactive substance to the tissue matrix.
5. The method of claim 4 , wherein the bioactive substance comprises an antimicrobial agent.
6. The method of claim 4 , wherein the bioactive substance comprises a cytokine.
7. The method of claim 4 , wherein the bioactive substance comprises a growth factor.
8. The method of claim 4 , wherein the bioactive substance comprises adipose tissue.
9. The method of claim 4 , wherein the bioactive substance comprises cells.
10. The method of claim 9 , wherein the cells comprise stem cells.
11. The method of claim 10 , wherein the stem cells comprise mesenchymal stem cells.
12. The method of claim 1 , further comprising adding a bioactive substance to the tissue matrix, the bioactive substance comprising one or more of an anti-microbial agent, cells, adipose tissue, growth factors, anti-inflammatory agents, steroids, and corticosteroids.
13. The method of claim 1 , wherein the arterial tissue matrix is a porcine matrix.
14. The method of claim 13 , wherein the arterial tissue matrix is derived from a pig that has been genetically modified to reduce or eliminate expression of α-1, 3-galactose moieties.
15. The method of claim 14 , wherein the pig lacks expression of α-galactosyltransferase.
16. The method of claim 1 , wherein the arterial tissue matrix includes elastins present in the arterial section from which the tissue matrix is derived.